Prognostic significance of fibrinogen-to-albumin ratio in patients with urological cancers: a meta-analysis

Aims The fibrinogen-to-albumin (FAR) ratio has been investigated as a predictor of the survival of patients with UCs (urological cancers), but definite conclusions are lacking. Therefore, this meta-analysis was performed to examine the prognostic value of FAR in patients with UCs.Materials and methods Eligible articles were identified by searching PubMed, Web of Science, Embase, and the Cochrane Library until 15 January 2026. The prognostic value of FAR in UCs was evaluated by calculating pooled hazard ratios (HRs) with 95% confidence intervals (CIs). The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS).Results Seven articles with 1996 patients were included in this meta-analysis. A high FAR significantly predicted poor OS (HR = 2.52, 95%CI = 2.04–3.11, p < 0.001) and unfavorable PFS (HR = 2.84, 95%CI = 2.22–3.64, p < 0.001) in patients with UCs. In the subgroup analyses, the predictive value of FAR for OS and PFS was not affected by study center, country, cancer type, tumor-node-metastasis stage, threshold, threshold analysis, or survival analysis (p < 0.05).Conclusion Our findings show that a higher FAR significantly predicted unfavorable OS and inferior PFS for patients with UCs, suggesting that FAR is a promising biomarker for predicting UC prognosis.